There are 169 resources available
27O - Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Ari Rosenberg
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 45O and 27O
Presenter: Irene Braña
Session: Abstract session 1
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Abstract session 1
Resources:
Webcast
Introduction
Presenter: Giovanni Abbadessa
Session: Oncology drug development: Biotech status and prospects
Resources:
Slides
Webcast
The Academia perspective
Presenter: Christophe Le Tourneau
Session: Oncology drug development: Biotech status and prospects
Resources:
Slides
Webcast
Panel discussion
Presenter: All Speakers
Session: Oncology drug development: Biotech status and prospects
Resources:
Webcast
Welcome to ESMO TAT 2024
Presenter: Anastasios Stathis
Session: Welcome to ESMO TAT 2024 and Honorary Award
Resources:
Slides
Webcast
Introduction to the 2024 TAT Honorary Award keynote lecture
Presenter: Elena Garralda
Session: Welcome to ESMO TAT 2024 and Honorary Award
Resources:
Slides
Webcast
Implementing precision oncology: From genomics to ADCs
Presenter: Funda Meric-Bernstam
Session: Welcome to ESMO TAT 2024 and Honorary Award
Resources:
Slides
Webcast